Articles related to ADVERSE EVENTS

In this updated analysis of the KEYNOTE-177 study, although pembrolizumab continued to show durable antitumor activity and fewer treatment-related adverse events compared with chemotherapy, there was no significant difference in overall survival between the two treatment groups.

Which AEs are most common with immunotherapy? Most concerning? Are some patients more likely to experience AEs? Should immunotherapy be used for patients with a pre-existing autoimmune condition? Do AEs predict response? Moffitt’s Dr. Hatem Soliman addresses these and other questions in this interview.

A study in the Annals of Internal Medicine looked at the association between cardiovascular outcomes and the coprescription of nitrates with PDE5 inhibitors in more than 42,000 men over a 10-year period. Two composite outcomes were measured: 1) cardiac arrest, shock, myocardial infarction, ischemic stroke, or acute coronary arteriography; and 2) syncope, angina pectoris, or drug-related adverse event. The authors found no statistically significant increase in measured cardiovascular AEs.

A systematic review identified 204 eligible publications from 2000 through 2017, with much of the evidence consisting of systematic reviews of observational data, consensus guidelines, case series, and case reports. Due to the paucity of high-quality evidence on management of immune-related adverse events, recommendations are based on expert consensus.

Presented at the ASCO20 Virtual Scientific Program, data from the 1,459 patients who were African American, Hispanic, Native American, Pacific Islander, or Asian highlighted the need for increased surveillance for cutaneous toxicity in patients with darker pigmented skin. Immune-related cutaneous adverse events (irCAEs) were assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.